CDKN2A (p16) mRNA decreased expression is a marker of poor prognosis in malignant high-grade glioma

  title={CDKN2A (p16) mRNA decreased expression is a marker of poor prognosis in malignant high-grade glioma},
  author={M. K. Sibin and D. Bhat and K. Narasingarao and C. Lavanya and G. K. Chetan},
  journal={Tumor Biology},
  • M. K. Sibin, D. Bhat, +2 authors G. K. Chetan
  • Published 2015
  • Biology, Medicine
  • Tumor Biology
  • Human high-grade glioma is heterogeneous in nature based on pathological and genetic profiling. Various tumour suppressor gene alterations are considered as prognostic markers in high-grade glioma. Gene expression of CDKN2A (p16) is used in various cancers as a prognostic biomarker along with methylation and deletion status of this gene. Expression levels of p16 mRNA were not studied as a biomarker in gliomas before. In this study, we have performed mRNA quantification analysis on 48 high-grade… CONTINUE READING
    15 Citations


    INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis.
    • R. Hui, R. Macmillan, +5 authors R. Sutherland
    • Biology, Medicine
    • Clinical cancer research : an official journal of the American Association for Cancer Research
    • 2000
    • 119
    Expression of cell cycle inhibitors p21, p27, p14 and p16 in gliomas. Correlation with classic prognostic factors and patients' outcome
    • 31
    Immunohistochemical detection of CDKN2, retinoblastoma and p53 gene products in primary astrocytic tumors.
    • 14
    Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas.
    • 72
    Combined aberrant expression of Bmi1 and EZH2 is predictive of poor prognosis in glioma patients
    • 29
    Downregulation of CDKN2A and suppression of cyclin D1 gene expressions in malignant gliomas
    • 28
    Patterns of expression of Rb and p16 in astrocytic gliomas, and correlation with survival.
    • 35